AQST-109 Sublingual Epinephrine Holds Up at Low Systemic Exposure

A pooled analysis presented at the ACAAI 2026 meeting indicates that the sublingual epinephrine film AQST-109 provides effective blood pressure responses even at low systemic exposure levels. The drug is currently under FDA review with a PDUFA goal date of March 2027.
Why it matters
This development offers a potential needle-free alternative for emergency allergy treatment, which could improve patient compliance and ease of use.
A pooled analysis presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix found healthy adults with the lowest exposure to sublingual epinephrine film AQST-109 still had greater blood pressure responses than with autoinjectors or intramuscular (IM) epinephrine.¹
The analysis addresses a recurring question about needle-free epinephrine: whether patients who absorb less drug through the sublingual route still achieve an adequate clinical response. Aquestive Therapeutics is developing AQST-109 as dibutepinephrine (Anaphylm), an epinephrine prodrug, and the US Food & Drug Administration (FDA) accepted the company’s New Drug Application (NDA) resubmission in October 2026 with a Prescription Drug User Fee Act (PDUFA) goal date of March 16, 2027.² The resubmission followed a January 30, 2026 complete response letter.³
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in